PetMed Express

PetMed Express, Inc. engages in the provision of markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The firm markets its products through national television, online and direct mail or print advertising campaigns. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

PetMed Express reports Q1 2023 earnings, anticipates growth from PetCareRx acquisition

PetMed Express faced sales decline, but the acquisition of PetCareRx and strong new customer growth provide optimism for future profitability. Financial stability, operational focus, and strategic partnerships position the company for long-term success.

PetMed Express reports Q3 sales dip but gains new customers

PetMed Express navigated challenges with a 3% decrease in YoY sales but gained 9% more net new customers. The company's focus on pet health expertise and expanding offerings positions it for future growth.
Despite advertising spending increases, PetMed maintains a strong balance sheet with over $102 million in unrestricted cash. Management's confidence in future prospects and innovative strategies bode well for the company's growth trajectory.

PetMed Express reports sales decline, eyes growth from acquisitions

PetMed Express focused on pet wellness, recent acquisitions, and strategic investments in telemedicine and pet insurance.
Despite sales decline in fiscal year 2023, the company aims for growth from the PetCareRx acquisition in 2024.
Challenges in over-the-counter medication sales and a net loss in Q4 were offset by a strong cash position and strategic focus on growth.

PetMed Express reports record revenue growth and expands pet insurance

PetMed Express (PETS) demonstrated strong financial performance in Q1 2024, with record-setting revenue growth and a focus on sustainable long-term growth.
The company's strategic initiatives, including the integration of the PetCareRx acquisition and expansion into the pet insurance market, position it for future success.
While facing challenges in a competitive market, PetMed Express has opportunities to solidify its market leadership in pet wellness and healthcare through customer-centric strategies.

PetMed Express reports Q2 growth, shifts focus to tech investments

PetMed Express (PETS) demonstrated solid financial performance in Q2 2024 with revenue growth and operational enhancements. While facing challenges in customer retention and market conditions, the company is strategically investing in technology and growth initiatives. With a focus on long-term sustainability and innovation, PetMed Express aims to drive growth and shareholder value in the pet health sector.

PetMed Express reports strong sales growth amidst accounting challenges

PetMed Express shows resilience in sales growth despite accounting challenges.
The company's focus on transparency and customer programs is a key strength.
Challenges include the need for a financial restatement and maintaining investor confidence.
Opportunities lie in strengthening internal controls and driving growth through acquisitions.

PetMed Express reports sales growth, invests in tech for future

PetMed Express (PETS) reported positive sales growth in Q4 2024 driven by the PetCareRx acquisition, despite a net loss due to acquisition-related expenses.
The company's customer-centric focus, strategic investments in technology, and strong leadership team additions position it well for future growth.
Challenges include managing expenses post-acquisition and navigating competitive pressures in the pet medications market, while opportunities exist in market expansion and operational enhancements.

PetMed Express (PETS) reports Q1 challenges but sees early improvements

PetMed Express (PETS) navigated a transition quarter with a focus on growth and profitability. Despite a sales decline and margin decrease, early signs of improvement were observed. The company emphasized optimizing cost structure, enhancing customer growth strategies, and implementing technology improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PetMed Express, Inc. provides markets prescription and non-prescription pet medications, health products and supplies for dogs and cats. Its non-prescription medications include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The prescription medications include heartworm preventatives, arthritis, thyroid, diabetes and pain medications, heart/blood pressure, and other specialty medications, and generic substitutes. The company was founded in January 1996 and is headquartered in Delray Beach, FL.

PetMed Express, Inc. (NASDAQ:PETS ) Q3 2023 Earnings Conference Call February 6, 2022 4:30 PM ET Company Participants Brian Prenoveau - IR Matthew Hulett - President & CEO Christine Chambers - CFO Conference Call Participants Erin Wright - Morgan Stanley Corey Grady - Jefferies Anthony Lebiedzinski - Sidoti & Company Operator Good afternoon, everyone, and thank you for joining the PetMed Express Third Quarter Earnings Conference Call. My name is Doug, the operator for today's call.

PetMed Express, Inc. (PETS) Q3 2023 Earnings Call Transcript

PetMed Express NASDAQ: PETS has struggled for years but may have finally hit bottom. The company's primary competitor, Chewy.com NASDAQ: CHWY, dominates and takes market share.

PetMed Express: Charts Say This Could Be The Bottom

PetMed Express, Inc. (NASDAQ:PETS ) Q4 2023 Earnings Conference Call May 22, 2023 4:30 PM ET Company Participants Brian Prenoveau - IR Matthew Hulett - President & CEO Christine Chambers - CFO Conference Call Participants Corey Grady - Jefferies Anthony Lebiedzinski - Sidoti & Company Operator Good afternoon, everyone, and thank you for joining the PetMed Express [Third Quarter] (sic) [Fourth Quarter] Earnings Conference Call. My name is Doug, the operator for today's call.

PetMed Express, Inc. (PETS) Q4 2023 Earnings Call Transcript

PetMed (PETS) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.30 per share a year ago.

PetMed (PETS) Misses Q4 Earnings and Revenue Estimates

Zoom Video

Markets were mixed on Monday. Zoom Video Communications moved slightly higher after boosting guidance.

2 Stocks to Watch on a Quiet Market Day

DELRAY BEACH, Fla., May 22, 2023 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health Expert™, today announced its financial results for its fourth quarter and fiscal year ended March 31, 2023.

PetMeds® Announces Its Fourth Quarter and Fiscal Year End Financial Results and Declares a Quarterly Dividend of $0.30 Per Share

Ms. Campos joins as an independent director, bringing years of executive leadership experience in digital transformations and turnarounds Ms. Campos joins as an independent director, bringing years of executive leadership experience in digital transformations and turnarounds

PetMeds® Appoints Sandra Y. Campos to its Board of Directors

Medical Properties Trust

High-yield dividend stocks have a rich tradition of delivering market-beating returns over long periods. As a result, these types of equities are often top buys for billionaire money managers.

2 High-Yield Dividend Stocks Billionaires Can't Stop Buying

DELRAY BEACH, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (PETS) (the “Company”), Your Trusted Pet Health Expert™ will hold a conference call on Monday, May 22, 2023 at 4:30pm Eastern time to discuss its financial results for the fourth quarter and full year ended March 31, 2023. Financial results will be issued in a press release prior to the call.

PetMed Express, Inc. Sets Fourth Quarter and Full Year 2023 Earnings Call

Big Lots

Enviva Partners

Intel

Kronos Worldwide

TELUS

Dividend stocks tend to be a strong equity subclass for investment in general. Most stocks that pay dividends tend to be stable because consistently returning earnings to shareholders is not always possible in weaker companies.

7 Dividend Traps to Avoid: Unmasking Risky Stocks With Shaky Business Outlooks

Walgreens

Companies need to grow their earnings to sustainably increase their dividends. Walgreens is struggling to drive fresh growth in its core segments.

2 Popular Dividend Stocks That Aren't as Safe as They Seem

PetMed Express is a leading national pet pharmacy with a long operating history and a solid reputation. While the company has benefitted from industry growth, they've been hurt by the competitive landscape.

PetMed Express: The Competitive Landscape Is A Tough Hurdle To Overcome

DELRAY BEACH, Fla., April 03, 2023 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (“PetMeds®”) (NASDAQ: PETS), Your Trusted Pet Health Expert™ completed its previously announced acquisition of PetCareRx, a leading supplier of pet medications, food, and supplies, for total consideration of approximately $36 million in an all-cash transaction.

PetMeds® Completes Acquisition of PetCareRx

Cinemark Holdings

Cutera

Ebix

GEO Group

GameStop

Children's Place

Block

Trupanion

Voya Financial

Short sellers are getting bold again. And they've picked their favorite stock market targets to crash.

Short Sellers Are Betting Serious Money 11 Stocks Will Crash Soon

BARK

Chewy

Rover Group

Petco Health and Wellness

Petco hit a new low on Wednesday following mixed quarterly results with weak guidance. Chewy was downgraded on Thursday after also warning of margin pressures in the coming year.

Why Are Pet Stocks Going to the Dogs Again?

B&G Foods

Cogent Communications Holdings

FAT Brands

Telephone and Data Systems

Via Renewables

When it comes to dividend investing, knowing which dividend stocks to sell can be more important than knowing which dividend stocks to buy. Buying stocks for income/yield can oftentimes be like trying to pick up pennies in front of a steamroller.

7 Overvalued Dividend Stocks to Sell Before It's Too Late

Its quarterly results included a surprise net loss.

Why PetMed Express Was a Dog of a Stock This Week

PetMed (PETS) delivered earnings and revenue surprises of -90.48% and 7.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PetMed (PETS) Lags Q3 Earnings and Revenue Estimates

PetMed Express, Inc. (NASDAQ:PETS ) Q3 2022 Earnings Conference Call February 6, 2022 4:30 PM ET Company Participants Brian Prenoveau - IR Matthew Hulett - President & CEO Christine Chambers - CFO Conference Call Participants Erin Wright - Morgan Stanley Corey Grady - Jefferies Anthony Lebiedzinski - Sidoti & Company Operator Good afternoon, everyone, and thank you for joining the PetMed Express Third Quarter Earnings Conference Call. My name is Doug, the operator for today's call.

PetMed Express, Inc. (PETS) Q3 2022 Earnings Call Transcript

DELRAY BEACH, Fla., Feb. 06, 2023 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health Expert™, today announced its financial results for its third quarter ended December 31, 2022.

PetMeds® Announces Its Third Quarter Financial Results and Declares a Quarterly Dividend of $0.30 Per Share

DELRAY BEACH, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (PETS) (the “Company”), Your Trusted Pet Health Expert™ will hold a conference call on Monday, February 6, 2023 at 4:30pm Eastern time to discuss its financial results for the third quarter ended December 31, 2022. Financial results will be issued in a press release prior to the call.

PetMed Express, Inc. Sets Third Quarter 2022 Earnings Call

Dick's Sporting Goods

Advisorshares Restaurant ETF

Amplify Online Retail ETF

Kroger

McDonald's

VanEck Vectors Retail ETF

Consumer Discretionary Select Sector SPDR Fund

Retail sales in the United States fell 1.1% sequentially in December 2022. Year-over-year, retail sales grew 9.2%.

ETFs & Stocks to Win Despite a Soft December Retail Sales

The Acquisition Is Expected to Accelerate Revenue Growth and Expand Addressable Market in a $120 Billion* U.S. Industry The Acquisition Is Expected to Accelerate Revenue Growth and Expand Addressable Market in a $120 Billion* U.S. Industry

PetMeds® to Acquire PetCareRx

Calavo Growers

Smith & Wesson Brands

Small-cap stocks that pay dividends can range from high-yield value stocks to faster-growing small-cap stocks. Here are five stocks that have growth potential and relative stability.

The 5 Best Small-Cap Dividend Stocks

The online pet pharmacy is in the early stages of expanding its sights, making it an interesting buy for risk-tolerant investors.

News for PetMed Express Stock (PETS)